French biotech firm Polyplus-transfection said this week that it has non-exclusively licensed its modified oligonucleotide technology to Germany's Metabion.
The agreement covers Polyplus' Zip Nucleic Acid oligonucleotides, which are modified oligonucleotides that have increased affinity for nucleic acids while retaining specificity.
Under the agreement, Metabion will be able to manufacture and commercialize custom ZNA oligonucleotides for research and in vitro diagnostics applications. Metabion, based in the Munich area, will begin commercializing the custom products later this month.
Polyplus, based in Strasbourg, said that its ZNA oligonucleotides, when used as primers or probes, improve the performance of molecular hybridization techniques such as PCR assays. ZNAs also increase the sensitivity of tests and detection of mutations, the company said.
Polyplus has also licensed its ZNA oligonucleotides to Sigma-Aldrich.
In December, Polyplus said that it raised €1.2 million ($1.8 million at the time) through a new funding round from existing investors; and said that it planned to add a new CEO and business development manager for its US operations.